Anzeige
Mehr »
Montag, 09.02.2026 - Börsentäglich über 12.000 News
Goldman sieht 15.000 USD bei Kupfer - dieser Explorer ist noch völlig unbekannt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
270 Leser
Artikel bewerten:
(1)

Sirius Medical: Pintuition Validated as a Safe and Reliable Navigation Solution by Large Real-World Data from the iBRA-NET study

EINDHOVEN, Netherlands, May 20, 2025 /PRNewswire/ -- Sirius Medical proudly announces positive results from the iBRA-NET localization study, confirming that Surgical Marker Navigation using the Sirius Pintuition® system is a highly effective and safe alternative to traditional wire-guided localization for impalpable breast lesions.

Pintuition Validated as a Safe and Reliable Navigation Solution by Large Real-World Data from the iBRA-NET study. Photo credit: Hannah Mornement/Profile Productions.

In the largest international multi-center patient cohort to date (n=1899), the study demonstrated that Pintuition achieved an excellent 99.4% localization success rate, comparable to that of a large wire-guided localization cohort (n=1170). Notably, Pintuition was associated with a significantly lower rate of positive margins (10.4% vs. 15.0%, p=0.013), while re-excision rates and overall safety outcomes did not differ significantly between the two groups.

"These results further validate the clinical value of Pintuition Surgical Marker Navigation," said Kitty Kempen, Director of Clinical & Medical Affairs at Sirius Medical. "They reinforce our mission to provide intuitive navigation solutions that enhance surgical precision, streamline workflows, and elevate the patient experience."

The Pintuition system offers surgeons a GPS-like navigation platform for precise tumor localization during breast-conserving surgery. It features TargetLOC®-a unique function that indicates when the probe is directly aligned above the Pintuition marker-combined with real-time audio and visual guidance. This enables unmatched precision, streamlines tumor localization, and overcomes the limitations of traditional wire-based methods.

"This is the largest prospective dataset to date comparing wire localization with a wireless alternative," said Mr. Edward St John, Principal Investigator of the iBRA-NET study. "The results demonstrate that Surgical Marker Navigation with Pintuition is non-inferior to wire-based localization. Pintuition is a highly effective technique with tangible benefits for patients and surgical teams alike."

The iBRA-NET Pintuition results were presented by Mr. Edward St John and Mr. Rajiv Dave during the 2025 Association of Breast Surgery (ABS) Conference, further underscoring the clinical relevance and momentum behind Surgical Marker Navigation in breast-conserving surgery. A full publication is expected in the coming months.

About iBRA-NET

The iBRA-NET is a multidisciplinary network of breast and plastic surgeons, allied healthcare professionals, and patients from across the UK. Guided by the mission "no innovation without evaluation," we are committed to the rigorous assessment of new surgical techniques, devices, and implants within the field of oncoplastic breast surgery.

Our work is supported by leading professional bodies, including the Association of Breast Surgery (ABS), the Royal College of Surgeons of England (RCSE), and the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS).

About Sirius Medical

With its roots deeply embedded in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivering unsurpassed yet affordable solutions that enable precise and efficient removal of tumors. The Pintuition® technology is simple, precise, affordable, CE-marked, and FDA-cleared. Sirius Medical is rapidly expanding with over 50,000 procedures worldwide in more than 250+ centers and a global commercial network covering the USA, Western Europe, Australia, and New Zealand.

Media Contact:

Benjamin Tchang
Global Marketing Director
Sirius Medical

+31 647 852 805
Benjamin.tchang@sirius-medical.com

Photo - https://mma.prnewswire.com/media/2691064/Pintuition.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/pintuition-validated-as-a-safe-and-reliable-navigation-solution-by-large-real-world-data-from-the-ibra-net-study-302460595.html

© 2025 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.